40 cents per share post approval:
It could represent 20,000 USA patients that renew 50% of their scripts with BOT getting 200 profit per $750 unit sale.
Kaken just had 272,000 new patients last 12 months.
40 cents?
If the US gets 200,000 patients like the above more like $4.
3 times the population more like $12
More effective sales and marketting more like $$$$$$$$$$
40 cents is still massively priced in to be a flop.
- Forums
- ASX - By Stock
- BOT
- Ann: Final Sofdra Labelling Discussions with FDA
Ann: Final Sofdra Labelling Discussions with FDA, page-249
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
Add BOT (ASX) to my watchlist
|
|||||
Last
32.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $588.2M |
Open | High | Low | Value | Volume |
32.5¢ | 33.5¢ | 32.5¢ | $1.302M | 3.974M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 713153 | 32.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
33.0¢ | 215665 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 63805 | 0.360 |
1 | 4000 | 0.355 |
1 | 698 | 0.335 |
4 | 246814 | 0.330 |
18 | 674697 | 0.325 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 25000 | 1 |
0.320 | 21875 | 1 |
0.325 | 3300 | 1 |
0.330 | 204191 | 5 |
0.335 | 329990 | 4 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |